LONG-TERM FOLLOW-UP-STUDY OF 164 PATIENTS WITH DEFINITE SYSTEMIC-SCLEROSIS - CLASSIFICATION CONSIDERATIONS

被引:21
作者
VAYSSAIRAT, M
BAUDOT, N
ABUAF, N
JOHANET, C
机构
[1] Department of Angiology, Broussais Hospital, Paris, 75014
[2] Department of Immunology, Saint Antoine Hospital, Paris, 75012
关键词
SCLERODERMA; SYSTEMIC SCLEROSIS; CONNECTIVE TISSUE DISEASE; RAYNAUDS PHENOMENON; CLASSIFICATION;
D O I
10.1007/BF02207193
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To evaluate the usefulness of recently proposed schemes of classification for systemic sclerosis an extensive cross-sectional study of a series of 164 consecutive patients with long-term systemic sclerosis was undertaken. There were 47 cases of proximal sclerosis, 93 of distal sclerosis and 24 of complete CREST syndrome. The study included clinical, visceral, immunological and follow-up data. In addition, a quantitative clinical score was calculated for each patient, thus providing indications for prognosis. Data were expressed according to three conventional systems of classification: The ARA system, the diffuse versus limited systemic sclerosis system and the early cutaneous involvement system. The most reliable indications of severe outcome were: proximal sclerosis, trunk skin involvement, presence of anti Scl 70 autoantibody, pulmonary and/or heart involvement and age. Diagnosis and prognosis were not generated by the same items. Prognosis indicators proved more accurate for groups than for individuals. Mortality was 1 death per 149 patient X years of follow-up from diagnosis. We conclude that the ARA criteria for classification should be recognized as a standard, but patients with complete CREST syndrome should be included in the distal group. Other systems of classification, principally 2-way versus 3-way criteria, allow different subsets of patients that correlate with prognosis and the severity of the disease, and could be used for therapeutic purposes.
引用
收藏
页码:356 / 363
页数:8
相关论文
共 45 条
  • [1] Tuffanelli D.L., Winkelmann R.K., Systemic scleroderma. A clinical study of 727 cases, Arch Dermatol, 84, pp. 359-371, (1961)
  • [2] Tuffanelli D.L., Winkelmann R.K., Diffuse systemic scleroderma. A comparison with acrosclerosis, Ann Intern Med, 57, pp. 198-203, (1962)
  • [3] Barnett A.J., Coventry D.A., Scleroderma: 1. clinical features, course of illness and response to treatment in 61 cases, Med J Aust, 1, pp. 992-1001, (1969)
  • [4] Rowell N.R., The prognosis of systemic sclerosis, Br J Dermatol, 95, pp. 57-60, (1976)
  • [5] Barnett A.J., Scleroderma (progressive systemic sclerosis): progress and course based on a personal series of 118 cases, Med J Aust, 2, pp. 129-134, (1978)
  • [6] Livingston J.Z., Scott T.E., Wigley F.M., Anhalt G.J., Bias W.B., McLean R.H., Hochberg M.C., Systemic sclerosis (scleroderma): clinical, genetic, and serologic subsets, J Rheumatol, 14, pp. 512-518, (1984)
  • [7] Cassani F., Tosti A., Bianchi F.B., Fusconi M., Selleri L., Baffoni L., Veronesi S., Volta U., Lenzi M., Pisi E., Clinical subsets of scleroderma: relevance of fluorescent and precipitating anti-nuclear antibodies, Clin Exp Rheum, 5, pp. 23-28, (1987)
  • [8] Masi A., D'Angelo W.A., Epidemiology of fatal systemic sclerosis (diffuse scleroderma) A 15-year survey in Baltimore, Ann Intern Med, 66, pp. 870-875, (1967)
  • [9] Medsger T.A., Masi A.T., Epidemiology of systemic sclerosis (scleroderma), Ann Intern Med, 74, pp. 714-721, (1971)
  • [10] Medsger T.A., Masi A.T., Rodnan G.P., Benedek T.G., Robinson H., Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients, Ann Intern Med, 75, pp. 369-376, (1971)